Update to rociletinib data with the RECIST confirmed response rate

New England Journal of Medicine

Volumn 374, Issue 23, 2016, Pages 2296-2297

  Sequist, Lecia V ^a   Soria, Jean Charles ^b   Camidge, D Ross ^c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ROCILETINIB; ACRYLAMIDE DERIVATIVE; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

BRAIN METASTASIS; CANCER GROWTH; DRUG RESPONSE; HUMAN; INTENTION TO TREAT ANALYSIS; LETTER; LUNG CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT OUTCOME; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE; FEMALE; GENETICS; LUNG NEOPLASMS; MALE;

ACRYLAMIDES; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84973931511     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1602688     Document Type: Letter

References (4)

1. Sequist LV, Soria J-C, Goldman JW, et al. Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med 2015;372:1700-9.
2. Clovis Oncology announces regulatory update for rociletinib NDA filing. Business Wire. November 16, 2015 (http://www.businesswire.com/news/home/20151116005513/en/).
3. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
4. Camidge DR, Sequist LV, Soria JC, et al. Activity of rociletinib in EGFR mutant NSCLC patients with a history of CNS involvement. Presented at the 16th World Conference on Lung Cancer, Denver, September 6-9, 2015.